Maven Securities LTD Mirati Therapeutics, Inc. Transaction History

Maven Securities LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$41.99 - $62.38 $1.47 Million - $2.18 Million	-35,000 Reduced 38.89%	55,000 $3.23 Million
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $2.5 Million - $4.08 Million	90,000 New	90,000 $3.92 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $462,653 - $921,218	-6,102 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $805,525 - $1.16 Million	6,102 New	6,102 $895,000
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $4.59 Million - $6.4 Million	-28,900 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $4.68 Million - $6.94 Million	28,900 New	28,900 $6.35 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.